How selinexor (Xpovio) is positioned in competitive R/R DLBCL market?

Karyopharm’s Selinexor (Xpovio) an oral selective inhibitor of nuclear export (SINE) compound inhibiting the nuclear export protein exportin 1 (XPO1) was granted accelerated approval for the treatment of adults with relapsed or refractory diffuse large […]